bluebird bio reports upbeat data

bluebird bio Inc. (Nasdaq: BLUE) reported positive updated data from an ongoing HGB-205 clinical study of LentiGlobin to treat severe sickle cell disease and transfusion-dependent B-thalassemia. Shares of the biotechnology firm leaped $30.65 to close at $201.80.